Multiple Top-line Phase 2 Clinical Efficacy Readouts from Wholly-owned Pipeline Anticipated in 2019 Etokimab Phase 2b Eosinophilic Asthma Trial Initiation Anticipated in 4Q19 IND Filing for Company’s Third Wholly-Owned Program, ANB030, an anti-PD-1 Agonist, Expected in 4Q19 Recognized $5.0 million

SAN DIEGO , Aug. 06, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will

Single dose of etokimab resulted in rapid and sustained lung function improvement and ACQ-5 score reduction through at least Day 64 Etokimab was well tolerated and no serious adverse events were reported Data supports infrequent dosing of etokimab in the treatment of eosinophilic asthma, which is